Ovarian cancer Cancer Malignant neoplasm of ovary
Conditions
Interventions
1. AHT Regimen: Adjuvant hormone therapy (AHT), type according to the preference of the patient's consultant, providing the prescribing practice is consistent. It is recommended that premenopausal wom
Sponsors
UK Co-ordinating Committee for Cancer Research (UKCCCR)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed epithelial ovarian cancer diagnosed within the last 9 months 2. Pre and/or postmenopausal 3. Chemotherapy and radiotherapy may be given at the discretion of the participating clinician, provided it does not include hormonal treatment other than that allocated in the trial 4. No history of hormone dependent malignancy 5. No contraindications to AHT
Exclusion criteria
Exclusion criteria: Patients for whom ovarian function has been deliberately preserved are excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed